Torbat Heydarieh University of Medical Sciences, Torbat Heydarieh, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
IUBMB Life. 2019 May;71(5):549-564. doi: 10.1002/iub.2011. Epub 2019 Feb 6.
Toll-like receptors (TLRs) play an important role in the innate and adaptive immune system. They are expressed in various regions of the female reproductive tract, and their regulation may be involved in the pathogenesis of gynecological lesions. There is growing evidence that ligands for several TLRs are potentially anticancer agents, some of which have already been approved by the FDA, and these compounds are now undergoing clinical evaluation. There is a rationale for using these ligands as adjuvants in the treatment or prevention of gynecological cancer. Some TLR agonists that are of potential interest in the treatment of gynecological lesions include imiquimod, motolimod, cervarix, and CpG-oligodeoxynucleotides (ODNs). In this review, we outline the different functions of TLRs in gynecological cancer with particular emphasis on the value of TLR agonists as a potential therapeutic target in the treatment of gynecological cancer. © 2019 IUBMB Life, 71(5):549-564, 2019.
toll 样受体 (TLRs) 在先天和适应性免疫系统中发挥重要作用。它们在女性生殖道的各个部位表达，其调节可能与妇科病变的发病机制有关。越来越多的证据表明，几种 TLR 的配体可能是抗癌药物，其中一些已经获得 FDA 批准，这些化合物正在进行临床评估。使用这些配体作为妇科癌症治疗或预防的佐剂是有道理的。一些在治疗妇科病变方面具有潜在意义的 TLR 激动剂包括咪喹莫特、莫罗莫德、佳达修和 CpG-寡脱氧核苷酸 (ODNs)。在这篇综述中，我们概述了 TLR 在妇科癌症中的不同功能，特别强调了 TLR 激动剂作为治疗妇科癌症的潜在治疗靶点的价值。
